Centchroman--a non-steroidal anti-cancer agent for advanced breast cancer: phase-II study.
Treatment with Centchroman (3,4-trans-2,2-dimethyl-3-phenyl-4-p-(beta-pyrrolidinoethoxy) phenyl-7-methoxy chroman) has been evaluated in 4 male and 75 female patients with advanced breast cancer. The overall response rate, including both male and female cases, was 40.5%. Among the female patients, the overall response rate was 38.7%. The median duration of response was 6 months. One of the 4 male patients showed a complete response and 2 showed partial responses. The responses were more marked for bone, pulmonary, soft tissue, skin and lymph-node metastases than for liver metastases.
Misra
N C
NC
Department of Surgery, K.G.'s Medical College, Lucknow, India.
Nigam
P K
PK
Gupta
R
R
Agarwal
A K
AK
Kamboj
V P
VP
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents; D001578:Benzopyrans / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000188:drug therapy*; D002486:Centchroman / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis
D000970:Antineoplastic Agents; D001578:Benzopyrans; D014408:Biomarkers, Tumor; D011960:Receptors, Estrogen; D002486:Centchroman